8-K: Ensysce Biosciences Announces $1.1 Million Registered Direct Offering Priced At-The-Market

Ensysce Biosciences has secured approximately $1.1 million through a registered direct offering and concurrent private placement to fund its TAAP and MPAR programs and for working capital.

Summary

• Ensysce Biosciences has entered into definitive agreements for a registered direct offering, expected to generate gross proceeds of approximately $1.1 million.
• The offering involves the issuance and sale of 315,188 shares of common stock (or common stock equivalents) at $3.49 per share.
• Concurrently, the company will conduct a private placement of unregistered Series A-5 and A-6 warrants, each to purchase up to 315,188 shares of common stock.
• The warrants have an exercise price of $3.24 per share and are exercisable immediately upon issuance.
• The Series A-5 warrants expire 18 months after issuance, while the Series A-6 warrants expire five years after issuance.
• H.C. Wainwright & Co. is the exclusive placement agent for the offering.
• Ensysce intends to use the net proceeds for continued development of its TAAP and MPAR programs and for working capital.
• The offering is expected to close on or about March 31, 2025, pending customary closing conditions.

Sentiment

Score: 6

Explanation: The announcement is neutral to slightly positive. While the company is raising capital, which can be dilutive, it is for the purpose of funding its key development programs. The at-the-market pricing suggests a fair deal for investors.

Positives

• The capital raised will support the continued development of Ensysce's TAAP and MPAR programs.
• The warrants provide potential future capital if exercised.
• The offering is priced at-the-market under Nasdaq rules.

Negatives

• The offering will dilute existing shareholders.
• The company's reliance on additional funding may indicate financial challenges.

Risks

• The closing of the offering is subject to customary closing conditions and may not occur.
• The company's plans for use of proceeds are subject to change.
• Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.

Future Outlook

The Company intends to use the net proceeds from the offering for continued development of its TAAP and MPAR programs and for working capital.

Industry Context

This announcement reflects a common financing strategy for clinical-stage pharmaceutical companies to raise capital for ongoing research and development activities.

Comparison to Industry Standards

• Comparable companies in the clinical-stage pharmaceutical sector, such as Zynerba Pharmaceuticals and BioDelivery Sciences International, often utilize registered direct offerings and private placements to secure funding for drug development programs.
• The terms of this offering, including the warrant coverage and exercise price, are generally consistent with industry standards for similar financings.
• The use of H.C. Wainwright & Co. as a placement agent is also common, as they specialize in advising and placing securities for small-cap and micro-cap companies in the healthcare sector.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The company's employees and management will benefit from the continued funding of development programs.
• Patients may benefit from the development of new pain relief options with reduced abuse and overdose potential.

Next Steps

• The offering is expected to close on or about March 31, 2025, subject to customary closing conditions.
• The Company will file a final prospectus supplement and an accompanying base prospectus with the SEC.
• The Company will continue development of its TAAP and MPAR programs.

Key Dates

Keywords

registered direct offering, private placement, warrants, TAAP, MPAR, capital raise, Ensysce Biosciences, financing